This September, Galderma launched a transformative skincare segment with Cetaphil’s new Skin Activator Hydrating & Firming Line, in partnership with actor and filmmaker Mariska Hargitay. The launch marks an entirely new skincare segment of advanced hydration and firming solutions designed specifically for improving the appearance of aging, thinning and fragile skin.
This summer, Galderma announced the launch of the Cetaphil Nourishing Oil to Foam Cleanser, a first-of-its-kind formula designed to deeply cleanse while preserving hydration and supporting the sensitive skin’s moisture barrier. Developed with dermatologists and brought to life through a vibrant team of medical experts and content creators, the cleanser sets a new standard for a gentle-yet-effective, hydrating cleanse.
Galderma has announced the establishment of its new U.S. headquarters in Miami, Florida, positioning the company at the heart of a thriving market for Dermatological Skincare and Injectable Aesthetics. Located in the vibrant Brickell neighborhood, the company expects to have approximately 150 employees, including U.S. leadership roles, based there by 2028.
In a new episode of Galderma’s video interview series Beauty x Medicine, we meet Dr. Jean Carruthers, a.k.a. ‘the godmother of cosmetic dermatology.’ She talks to our CEO, Flemming Ørnskov, MD, MPH, about key learnings from her extraordinary career: the importance of listening to patients, how she convinced peers and patients to embrace her groundbreaking treatment, and how exciting innovations continue to reshape the injectable aesthetics field.
Galderma recently launched the Alastin Skincare Restorative Skin Complex with Next Generation TriHex Technology®: a newly enhanced daily rejuvenating serum designed to support collagen production while addressing visible volume loss.
Phase III trial results for the first and only ready-to-use liquid form of RelabotulinumtoxinA, created using Galderma’s proprietary PEARL(TM) technology, were recently published in Aesthetics Surgery Journal. The results showed high patient-assessed efficacy and satisfaction in the treatment of glabellar (frown) lines. The product has been approved in 15 European countries, with launches ahead of schedule in early 2025.
Galderma received U.S. FDA for its novel biologic treatment for patients with moderate-to-severe atopic dermatitis.
Galderma delivered record first quarter 2025 net sales of 1.129 billion USD, including strong performance from two launches with blockbuster potential.
An in-depth interview of our CEO, Flemming Ørnskov, with Marc Champagne on Behind the Human Podcast. During the conversation, many topics are discussed including pivotal experiences that shaped his early life, through to the future for Galderma.
In the inaugural episode of Beauty x Medicine, Dr. Shawn Kwatra joins our CEO, Flemming Ørnskov, MD, MPH, to delve deep into uncovering the science of skin. Sharing key insights, Dr. Kwatra discusses the outsized, and at times overlooked, impact of chronic itch of unknown origin on quality of life. He also explores dermatological research in skin of color and the role of AI in personalized care, among other key topics. Beauty x Medicine underscores our commitment at Galderma to collaboration and conversation. By regularly engaging in conversations with key voices in our industry, we’re unpacking the trends and forces shaping the future of dermatology to advance dermatology for every skin story.
